CGON 250516 25.00C(CGON250516C25000) Stock Price Today | Quotes & News - Moomoo

US OptionsDetailed Quotes

CGON250516C25000

Watchlist

2.80
-0.20-6.67%

15min DelayTrading Apr 30 11:15 ET

2.80High2.80Low

Intraday

5D
Daily

News

RBC Capital Maintains CG Oncology(CGON.US) With Buy Rating, Raises Target Price to $68
Moomoo NewsApr 29 19:31 ET · Ratings
BofA Securities Initiates CG Oncology(CGON.US) With Buy Rating, Announces Target Price $63
Moomoo NewsApr 29 19:31 ET · Ratings
CG Oncology Is Maintained at Outperform by RBC Capital
Dow JonesApr 29 13:25 ET · Ratings
Buy Rating for CG Oncology, Inc. Driven by Cretostimogene's Potential in Bladder Cancer Treatment Amid BCG Shortage
TipRanksApr 29 08:15 ET · Ratings
RBC Raises Price Target on CG Oncology to $68 From $66, Keeps Outperform, Speculative Risk
MT NewswiresApr 29 06:50 ET · Ratings
CG Oncology Stock (CGON) Surges 25% As Cancer Drug Shows Remarkable Results
TipRanksApr 28 22:18 ET

Comments

CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeti

$CG Oncology (CGON.US)$
Breakthrough: CG Oncology's Bladder Cancer Treatment Achieves 42% Complete Response Rate with 28-Month Durability

CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeti

CG Oncology Announces Best-in-Disease Durability Data in BOND-003 Cohort C and Promising Early Signal in Cohort P for Cretostimogene Grenadenorepvec at the American Urological Association Annual Meeti

CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates

$CG Oncology (CGON.US)$
CG Oncology's Bladder Cancer Drug Shows 75.5% Success Rate as Cash Reserves Hit $742M

CG Oncology Reports 2024 Year End Financial Results and Provides Business Updates

Nov 25, 2024 22:57

$CG Oncology (CGON.US)$ fly

May 22, 2024 15:52

Biotech Stock Catalyst Watchlist 👀

🎯 Ph 2 readouts in Q2 2024...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...

Biotech Stock Catalyst Watchlist 👀

Biotech Stock Catalyst Watchlist 👀

20

3

3

Apr 18, 2024 16:34

🎯 Ph 3 readouts in Q2 2024...

$Travere Therapeutic (TVTX.US)$ Phase 3
$CG Oncology (CGON.US)$ Phase 3
$United Therapeutics (UTHR.US)$ Phase 3
$United Therapeutics (UTHR.US)$ Phase 3
$BioCardia (BCDA.US)$ Phase 3
$Insmed (INSM.US)$ Phase 3
$GlycoMimetics (GLYC.US)$ Phase 3
$Annexon (ANNX.US)$ Phase 3
$Lipocine (LPCN.US)$ Phase 3
$FibroGen (FGEN.US)$ Phase 3
$UroGen Pharma Ltd (URGN.US)$ Phase 3
$Lyra Therapeutics (LYRA.US)$ Phase 3
$Citius Pharmaceuticals (CTXR.US)$ Phase 3
$Jaguar Health (JAGX.US)$ Phas...

🎯 Ph 3 readouts in Q2 2024...

20

4

Read more